{{Rsnum
|rsid=7331762
|Gene=HS6ST3
|Chromosome=13
|position=96193303
|Orientation=plus
|GMAF=0.4192
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=HS6ST3
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 27.4 | 47.8 | 24.8
| HCB | 14.7 | 44.1 | 41.2
| JPT | 9.7 | 42.5 | 47.8
| YRI | 15.9 | 48.3 | 35.9
| ASW | 17.5 | 52.6 | 29.8
| CHB | 14.7 | 44.1 | 41.2
| CHD | 18.5 | 44.4 | 37.0
| GIH | 14.9 | 51.5 | 33.7
| LWK | 13.6 | 40.0 | 46.4
| MEX | 17.5 | 57.9 | 24.6
| MKK | 7.1 | 41.9 | 51.0
| TSI | 24.5 | 48.0 | 27.5
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs7331762
|Name_s=
|Gene_s=HS6ST3
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 176. Study population/ethnicity: 87 European descent Caucasians and 89 Yorubans. Significance metric(s): p = 0.00009. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109418
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs7331762
|overall_frequency_n=50
|overall_frequency_d=128
|overall_frequency=0.390625
|n_genomes=35
|n_genomes_annotated=0
|n_haplomes=44
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=24371161
|Title=Association of HS6ST3 gene polymorphisms with obesity and triglycerides: gene x gender interaction
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}